All In Biotech

Drug Trial Radar · NCT07247058

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Isturisa in Management of Mild Autonomous Cortisol Secretion (MACS)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Dec 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Recordati Rare Diseases Inc
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.

Conditions

  • Mild Autonomous Cortisol Secretion (MACS)

Interventions

  • Osilodrostat (Isturisa)Drug

    The intervention aims to evaluate the impact of osilodrostat on cardiometabolic outcomes, bone mineral density, body composition, adrenal tumor size or hyperplasia, and biochemical markers of cortisol excess.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in fasting glucose, HbA1cTime frame: Baseline, and then every 3 months up to 2 years
  2. Change in bone mineral density (g/cm²)Time frame: Baseline, 1 year, and 2 years
  3. Change in body weight (kg) from baseline during Isturisa treatmentTime frame: Baseline and every 3 months up to 2 years
  4. Change in lipid profile from baseline during Isturisa treatmentTime frame: Baseline and every 3 months up to 2 years
  5. Change in body composition (kg)Time frame: baseline, 1 year and 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.